Effect of Receiving Intravenous Vitamin C on Dyslipidemia in Patients Undergoing Hemodialysis

Document Type : Original Quantitative and Qualitative Research Paper


1 MS in Critical Care Nursing, School of Nursing, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Instructor of Nursing, Department of Medical Surgical Nursing, School of Nursing, Baqiyatallah University of Medical Sciences, Tehran, Iran

3 Assistant Professor of Nursing, Department of Medical Surgical Nursing, School of Nursing, Baqiyatallah University of Medical Sciences, Tehran, Iran

4 Assistant Professor of Nephrology and Urology, Department of Nephrology and Urology, Medical School, Baqiyatallah University of Medical Sciences, Tehran, Iran


Background: Dyslipidemia is one of the major causes of the production and progression of atherosclerosis in hemodialysis patients. Vitamin C is able to improve dyslipidemia by reducing an oxidative stress.
Aim: The aim of this study was to evaluate the effect of vitamin C supplementation on dyslipidemia in hemodialysis patients.
Methods: In a randomized, double-blind clinical trial, 160 patients with chronic renal failure were studied. They were divided into three groups (intervention, control and witness). In an intervention group, 250 mg from vitamin C was injected, three times weakly at the end of each dialysis session via the intravenous route, for 8 weeks. In the control group same amount of placebo saline was injected and in the witness group no intervention was performed. Required laboratory parameters including serum total cholestrole, triglyserid and HDL were measured at the beginning and end of the intervention. In order to analyze the data, SPSS statistical software was used, and test Chi square and ANOVA were performed. P value less than 0.05 is considered statistical significance.
Results: No significant differences were observed in the serum levels of cholesterol, triglyceride and HDL between groups before and after the intervention.
Conclusion: The results of this study demonstrated that 250 mg intravenous vitamin C did not change serum levels of cholesterol, triglyceride and HDL.


1- Hosseinpanah F, Kasraei F, Nassiri A, Azizi F. High Prevalence of Chronic Kidney Disease in Iran: a Large Population-based Study. BMC public Health 2009.
2- Arjmand M, Seif A, Raji A. Kidney and urinary tract diseases. In Translation Harrison Principles of Internal Medicine. Tehran: Arjmand;2008 (Persian)
3- Khazaee M, Derakhshan A. Effects of Oral L-carnitine in Children with Hyperlipidemia Undergoing Chronic Hemodialysis. Journal of Mashhad University of Medical Sciences. 2007; 91(49).49-56. (Persian)
4- Drüeke TB, Massy ZA. Atherosclerosis in CKD: Differences from the General Population. Nat Rev Nephrol. 2010;6:723–35. Doi: 10.1038/nrneph.2010.143  
5- Homma K, Homma Y, Yamaguchi S, Shiina Y, Wakino S, Hayashi K, Hori S, Itoh H. Triglyceride-rich Lipoproteins in Chronic Kidney Disease Patients Undergoing Maintenance Haemodialysis Treatment. Int J Clin Pract. 2012 Apr; 66(4):394-8. Doi: 10.1111/j.1742-1241.2011.02862.x.
6- Heymann EP, Kassimatis TI, Goldsmith DJ. Dyslipidemia, Statins, and CKD Patients' Outcomes - Review of the Evidence in the Post-sharp era. J Nephrol. 2012 Jul-Aug; 25(4):460-72. Doi: 10.5301/jn.5000154.
7- Gallieni M, Caputo F, Filippini A, Gabella P, Giannattasio M, Stingone A, Farina M. Prevalence and Progression of Cardiovascular Calcifications in Peritoneal Dialysis Patients: A Prospective Study. Bone. 2012 Sep; 51(3):332-7.
8- Bakris GL. Lipid Disorders in Uremia and Dialysis. Contrib Nephrol. 2012 May 25; 178:100-5. Doi: 10.1159/000337821.
9- Imamura H,Mizuuchi K,Oshikata R. Physical Activity and Blood Lipids and Lipoproteins in Dialysis Patients. Int J Nephrol. 2012; 2012:106914. 1-6. doi:  10.1155/2012/106914; 2012: 106914. 
10- Kujawa-Szewieczek A, Więcek A, Piecha G. The Lipid Story in Chronic Kidney Disease: a Long Story with a Happy End? Int Urol Nephrol. 2012 Oct 2; 96(8). 1-15. DOI 10.1007/s11255-012-0296-8
11- Tu SF, Chou YC, Sun CA, Hsueh SC, Yang T. The Prevalence of Metabolic Syndrome and Factors Associated with Quality of Dialysis among Hemodialysis Patients in Southern Taiwan. Glob J Health Sci. 2012 Jul 18; 4(5):53-62. Doi: 10.5539/gjhs.v4n5p53. 
12- Handelman G.  Vitamin C Deficiency in Dialysis Patients- are We Perceiving the Tip of an Iceberg? Nephrol Dial Transplant .2006; 22(2).328-31
13- Makówka A, Dryja P, Chwatko G, Bald E, Nowicki M. Treatment of Chronic Hemodialysis Patients with Low-dose Fenofibrate Effectively Reduces Plasma Lipids and Affects Plasma Redox Status. Lipids Health Dis. 2012 Jul 6; 11:47.2-7. Doi:  10.1186/1476-511X-11-47.
14- Vitamin C. ExRx.net, Nutrition, Antioxidants.2012
15- The Office of Dietary Supplements provides information.  NIH Office of Dietary Supplements. Dietary Supplement Fact Sheet: Vitamin C. Reviewed: June 24, 2011
16- Singer R, Rhodes H, Chin G, Kulkarini H, Ferrari P. High Prevalence of Ascorbate Deficiency in an Australian Peritoneal Dialysis Population. Nephrology 2008; 13:17-22.
17- Levine M, Rumsey SC, Daruwla R. Criteria and Recommendations for Vitamin C Intake. JAMA 1999; 281, 1415-23
18- Ahmed J, Weisberg LS. Hyperkalemia in Dialysis Patients. Semin Dial 2001; 14:348-56
19- Jackson P, Loughrey CM, Lightbody JH. Effect of Hemodialysis on Total Antioxidant Capacity and Serum Antioxidants in Patients with Chronic Renal Failure. Clin Chem 1995;41:1135-8.
20- Morena M, Cristol JP, Bosc JY. Convective and Diffusive Losses of Vitamin C During Hemodiafiltration Ssession: a Contributive Factor to Oxidative Stress in Hemodialysis Patients. Nephrol Dial Transplant 2002; 17: 422-27.
21- Ramos R, Gómez-Geriqué N, Martínez-Castelao A. Lipoprotein Oxidation Profile in End Stage Renal Disease Patients. Role of Vitamin C Supplementation. Nefrologia. 2005; 25(2):178-84.
22- Aghighi M, Heidary Rouchi A, Zamyadi M, Mahdavi-Mazdeh M, Rajolani H, Ahrabi S. Dialysis in Iran. Iran J Kidney Dis. 2008;2(1):5-11
23- News Code: 153300. Publish data:10/4/2011; 13:23. mailto:info@fardanews.com
24- There are No Statistics for the Number of Kidney Patients. Etemad journal. 2347 number. 15/12/1390
25- Ravanshad SH, Nasrollah Zade J, Sovaid M, Sotoudemaram A. Effect of Sour Orange (Citrus Aurantium L.) Juice Consumption on Blood Glucose and Lipid Profile in Diabetic Patients with Dyslipidemia. Journal of Gilan University of Medical Sciences.2006; 57(15).48-53. (Persian)
26- Framingham ATPIII score. Adapted from Adult Treatment Panel III at file:www.nhlbi.nih.gov. 2012 UpToDate
27- Rafiei M, Sadr S M H, Nasirian M, Namayandeh S M, Abdoli A M, Sadr S M. Dyslipidemia in Diabetic Patients: a Cross Sectional Study in Urban Population of Yazd, Iran. Tehran UniversityMedical Journal. Oct 2008; 66( 7): 503-7 (Persian)
28- Nabipour I, Vafajou F, Mohajeri M S, Salimipour H, and Aboutalebi SH, Andalib P. Hyperlipidemia Disorders in CVA in Boushehr. Diabete and Lipid of Iran Journal. 2003; 2(1): 31-8 (Persian)
29- Biranvand M, Asadpour M. Dyslipidemia in Acute Coronory Syndrome. Journal of Pajouhande. 2007; 54(11).377-84 (Persian)
30- Emami Naini A, Moradi M, Mortazavi M, Hadizadeh M, Shirani F, Gholamrezaei A, Basir Ghafouri H. Effects of Carnitine Supplement on Dyslipidemia and Anemia in hemodialysis Patients. Journal of Isfahan Medical School. 2011 julv; 139(29).596-604. (Persian)
31- Kurowska EM, Spence JD, Jordan J. HDL- Cholesterol- Raising Effect of Orange Juice in Subjects with Hypercholesterolemia. Am J Clin Nutr 2000; 72: 1095-100